Last updated on February 2018

Safety and Efficacy Assessment of Monoprost in Comparison With Lumigan 0.01 % and Lumigan 0.03% Unit Dose

Brief description of study

Primary objective:

The primary objective is to demonstrate the superiority of Monoprost versus Lumigan 0.01% and Lumigan 0.03% Unit Dose in term of safety with respect to the assessment of conjunctival hyperaemia in the worse eye at Day 84.

The conjunctival hyperaemia will be scored using the MacMonnies photographic scale (0 to 5).

Clinical Study Identifier: NCT02017327

Find a site near you

Start Over

Laboratoires Th a

Clermont ferrand, France
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.